JP2006526025A5 - - Google Patents

Download PDF

Info

Publication number
JP2006526025A5
JP2006526025A5 JP2006514998A JP2006514998A JP2006526025A5 JP 2006526025 A5 JP2006526025 A5 JP 2006526025A5 JP 2006514998 A JP2006514998 A JP 2006514998A JP 2006514998 A JP2006514998 A JP 2006514998A JP 2006526025 A5 JP2006526025 A5 JP 2006526025A5
Authority
JP
Japan
Prior art keywords
disease
compound
infection
och
pharmaceutical product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006514998A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006526025A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/016831 external-priority patent/WO2005030120A2/en
Publication of JP2006526025A publication Critical patent/JP2006526025A/ja
Publication of JP2006526025A5 publication Critical patent/JP2006526025A5/ja
Withdrawn legal-status Critical Current

Links

JP2006514998A 2003-05-28 2004-05-28 抗血管新生剤 Withdrawn JP2006526025A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47428803P 2003-05-28 2003-05-28
PCT/US2004/016831 WO2005030120A2 (en) 2003-05-28 2004-05-28 Antiangiogenic agents

Publications (2)

Publication Number Publication Date
JP2006526025A JP2006526025A (ja) 2006-11-16
JP2006526025A5 true JP2006526025A5 (enExample) 2007-07-26

Family

ID=34392892

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006514998A Withdrawn JP2006526025A (ja) 2003-05-28 2004-05-28 抗血管新生剤

Country Status (6)

Country Link
US (3) US7371741B2 (enExample)
EP (1) EP1633367A2 (enExample)
JP (1) JP2006526025A (enExample)
AU (1) AU2004275693A1 (enExample)
CA (1) CA2527074A1 (enExample)
WO (1) WO2005030120A2 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US20040214807A1 (en) * 1993-08-06 2004-10-28 D'amato Robert J. Estrogenic compounds as anti-mitotic agents
US6346510B1 (en) * 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US7135581B2 (en) * 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
WO2005030120A2 (en) * 2003-05-28 2005-04-07 Entremed, Inc. Antiangiogenic agents
CA2558036A1 (en) * 2004-03-09 2005-09-22 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamine aspartyl protease inhibitors
US20070004689A1 (en) * 2004-03-12 2007-01-04 Agoston Gregory E Antiangiogenic agents
EP1756139A4 (en) * 2004-03-12 2009-07-29 Entremed Inc ANTI-ANGIOGENIC AGENTS
EP1819343A2 (en) * 2004-11-29 2007-08-22 EntreMed, Inc. A method of administering anti-angiogenic agents and a method of treating disease using same
US20060264413A1 (en) * 2005-04-18 2006-11-23 Sri International Method and composition for inhibiting cell proliferation and angiogenesis
US8168621B2 (en) 2005-09-30 2012-05-01 Endece, Llc 6-substituted estradiol derivatives and methods of use
US20080119447A1 (en) * 2005-09-30 2008-05-22 James Yarger 6-alkoxyalkyl estradiol derivatives and methods of use
US10174070B2 (en) 2005-09-30 2019-01-08 Endece Llc 6-substituted estradiol derivatives and methods of use
WO2007059111A2 (en) * 2005-11-14 2007-05-24 Entremed, Inc. Anti-angiogenic activity of 2-methoxyestradiol in combination with anti-cancer agents
CA2646065C (en) * 2006-03-20 2014-01-14 Entremed, Inc. Disease modifying anti-arthritic activity of 2-methoxyestradiol
WO2008094665A1 (en) * 2007-01-31 2008-08-07 Entremed, Inc. Method of treating amyloidosis mediated diseases
WO2009003110A2 (en) * 2007-06-26 2008-12-31 Children's Medical Center Corporation Metap-2 inhibitor polymersomes for therapeutic administration
CZ300376B6 (cs) * 2008-05-05 2009-05-06 Prírodovedecká Fakulta Uk Ligandy estrogenových receptoru alfa a beta, zpusob jejich prípravy a farmaceutické prostredky, které je obsahují
EP2334686B1 (en) 2008-08-28 2019-02-27 President and Fellows of Harvard College Cortistatin analogues and syntheses therof
WO2010123545A2 (en) * 2009-04-22 2010-10-28 President And Fellows Of Harvard College Angiogenesis inhibitors
CA2800260C (en) * 2010-04-19 2013-07-09 Sri International Compositions and method for the treatment of multiple myeloma
FR2975008B1 (fr) * 2011-05-13 2014-03-07 Inst Biophytis Utilisation de composes et composition pour le traitement de la degenerescence maculaire liee a l'age (dmla)
MY180383A (en) 2013-12-24 2020-11-28 Harvard College Cortistatin analogues and syntheses and uses thereof
EP3294298A4 (en) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin analogues, syntheses, and uses thereof
EP3316889A4 (en) 2015-07-01 2018-11-14 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
KR20210044589A (ko) * 2019-10-15 2021-04-23 재단법인 한국파스퇴르연구소 2-메톡시에스트라디올 유도체 및 이들의 의약 용도
CN111041062B (zh) * 2019-12-19 2021-11-16 山东赛托生物科技股份有限公司 一种甾体化合物的制备方法

Family Cites Families (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US596245A (en) * 1897-12-28 Hinge for ink-well caps
US2584271A (en) 1948-06-19 1952-02-05 Searle & Co Steroid derivatives and method for producing the same
GB857080A (en) 1956-05-29 1960-12-29 Syntex Sa Cyclopentanophenanthrene derivatives and process for the production thereof
GB857081A (en) 1956-05-29 1960-12-29 Syntex Sa Cyclopentanophenanthrene derivatives and process for the production thereof
US3166577A (en) 1956-05-29 1965-01-19 Syntex Corp 1, 2-dimethyl estrogens and intermediates used in the production thereof
US2846453A (en) 1957-05-28 1958-08-05 Searle & Co Alpha-ring-acylated estrone derivatives, and corresponding alcohols, their esters, and ethers
DE1907330U (de) 1964-04-13 1964-12-23 Standard Elektrik Lorenz Ag Maschine zum einfuehren von einlagen in briefumschlaege.
US3562260A (en) 1965-08-23 1971-02-09 Ormonoterapia Richter Spa 2-carbonyl-estratrienes and method of their preparation
US3470218A (en) 1966-12-27 1969-09-30 Allied Chem New 2-substituted estrogenic steroids
US3410879A (en) 1967-04-12 1968-11-12 American Home Prod Process for preparing gonahexaenes
US3492321A (en) 1968-01-22 1970-01-27 Syntex Corp Cyclopropenyl estra, -1,3,5(10)-trienes
US3496272A (en) 1968-01-23 1970-02-17 American Home Prod Ester of 3-(2-propynyloxy)-estradiol
DE2004516A1 (en) 1969-03-05 1970-09-10 VEB Jenapharm, Jena Thermpentic steroidal sulphonate esters
GB1502635A (en) 1974-02-27 1978-03-01 Schering Ag Process for splitting steroid ethers
JPS5265259A (en) 1975-11-27 1977-05-30 Takeda Chem Ind Ltd Synthesis of 16beta-alkylestradiol or its 17-esters
NL7613248A (nl) 1976-11-26 1978-05-30 Akzo Nv Werkwijze voor het bereiden van nieuwe steroid- esters.
US4172132A (en) 1977-07-26 1979-10-23 Schering Corporation 1,3,5(10),6,8,14-19-Nor-pregnahexaenes, their use as anti-psoriatic agents, and pharmaceutical formulations useful therefor
DE2757157C3 (de) 1977-12-19 1980-10-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen Verfahren zur Herstellung von 16 a -alkylierten Steroiden
FR2515188A1 (fr) 1981-10-27 1983-04-29 Roussel Uclaf Nouveaux derives du 3-amino-pregn-5-ene, leurs sels, procede de preparation, application a titre de medicaments et compositions les renfermant
JPS58131978U (ja) 1982-03-01 1983-09-06 日産自動車株式会社 空気噴射式織機の緯糸の案内通路を有する筬
US4994443A (en) 1982-12-20 1991-02-19 The Children's Medical Center Corporation Inhibition of angiogenesis
US5001116A (en) 1982-12-20 1991-03-19 The Children's Medical Center Corporation Inhibition of angiogenesis
JPS60126096A (ja) 1983-12-12 1985-07-05 Olympus Optical Co Ltd フロ−インジエクシヨン分析方法
US4552758A (en) 1983-12-20 1985-11-12 St. Jude Children's Research Hospital Human use of avian-human reassortants as vaccines for influenza A virus
US4522758A (en) 1983-12-22 1985-06-11 Eli Lilly And Company Method of preparing 2-fluoro-17β-estradiol
EP0166937B1 (en) 1984-06-06 1991-08-28 Abbott Laboratories Adrenergic compounds
US4634705A (en) 1984-06-06 1987-01-06 Abbott Laboratories Adrenergic amidines
SU1240038A1 (ru) 1984-11-23 1996-10-27 Уральский политехнический институт им.С.М.Кирова 3-оксиэстра-1,3,5-триен-17-гидразон, обладающий гормональной и противоопухолевой активностью
US4917826A (en) 1985-10-18 1990-04-17 The Upjohn Company Cyclic hydrocarbons with an aminoalkyl sidechain
JPS62135472A (ja) 1985-12-10 1987-06-18 Yakult Honsha Co Ltd 新規な１，２−ビス−３，５−ジオキソピペラジニルエタン誘導体
US4743597A (en) 1986-01-27 1988-05-10 Javitt Norman B Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases
DE3625315A1 (de) 1986-07-25 1988-01-28 Schering Ag 11ss-(4-isopropenylphenyl)-estra-4,9-diene, deren herstellung und diese enthaltende pharmazeutische praeparate
JP2517561B2 (ja) 1986-10-03 1996-07-24 新技術事業団 カテコ−ルエストロゲンのイムノアツセイキツド
US5352664A (en) 1986-10-31 1994-10-04 Board Of Regents, The University Of Texas System Thrombin derived polypeptides; compositions and methods for use
JPS63119500U (enExample) 1987-01-30 1988-08-02
AU1628288A (en) 1987-04-16 1988-11-04 Upjohn Company, The Cyclic hydrocarbons with an aminoalkyl sidechain
US4808402A (en) 1987-05-29 1989-02-28 Northwestern University Method and compositions for modulating neovascularization
US5135919A (en) 1988-01-19 1992-08-04 Children's Medical Center Corporation Method and a pharmaceutical composition for the inhibition of angiogenesis
AU5640390A (en) 1989-06-16 1991-01-08 Upjohn Company, The Suramin type compounds and angiostatic steroids to inhibit angiogenesis
IT1247827B (it) 1991-02-05 1995-01-02 Erba Carlo Spa Benzoil carbinolo e suoi esteri, utili come inibitori dell'angiogenesi
WO1993003729A1 (en) 1991-08-12 1993-03-04 Research Corporation Technologies, Inc. N-substituted phenoxazines for treating multidrug resistant cancer cells
US6011024A (en) * 1991-08-28 2000-01-04 Imperial College Of Science Technology & Medicine Steroid sulphatase inhibitors
WO1993010805A1 (en) 1991-12-02 1993-06-10 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human pdgf beta receptor
GB9207437D0 (en) 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
DE4235657A1 (de) 1992-10-22 1994-06-23 Schering Ag Verfahren zum Alkylieren von Östronderivaten
AU6955394A (en) 1993-01-11 1994-08-15 Tsumura & Co. Vascularization inhibitor and novel compound
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
ATE246513T1 (de) 1993-05-27 2003-08-15 Entremed Inc Zubereitungen und verfahren für die behandlung von krebs und hyperproliferierenden krankheiten
US5643900A (en) 1993-07-02 1997-07-01 Fotsis; Theodore Method for treatment of pathological conditions associated with angiogenesis and preparation therefor
US5886026A (en) 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
US20040214807A1 (en) * 1993-08-06 2004-10-28 D'amato Robert J. Estrogenic compounds as anti-mitotic agents
US6908910B2 (en) 1993-08-06 2005-06-21 The Children's Medical Center Corporation Estrogenic compounds as anti-mitotic agents
US5504074A (en) 1993-08-06 1996-04-02 Children's Medical Center Corporation Estrogenic compounds as anti-angiogenic agents
CA2137639C (en) 1993-12-09 1999-01-26 Agustin B. L. Davila Vaccine composition comprising autologous epidermal growth factor or a fragment or a derivate thereof having anti-tumor activity and use thereof in the therapy of malignant diseases
US5646136A (en) 1994-01-04 1997-07-08 Duke University Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids
US5639725A (en) 1994-04-26 1997-06-17 Children's Hospital Medical Center Corp. Angiostatin protein
CA2188813C (en) 1994-04-26 2010-08-03 Michael S. O'reilly Angiostatin protein, nucleic acids encoding the same and methods of detection
US5837682A (en) 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
US5521168A (en) 1994-10-13 1996-05-28 Alcon Laboratories, Inc. Estrogen metabolites for lowering intraocular pressure
US5861372A (en) 1996-02-22 1999-01-19 The Children's Medical Center Corporation Aggregate angiostatin and method of use
US5854205A (en) 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
US6346510B1 (en) 1995-10-23 2002-02-12 The Children's Medical Center Corporation Therapeutic antiangiogenic endostatin compositions
US5854221A (en) 1996-12-12 1998-12-29 The Children's Medical Center Corporation Endothelial cell proliferation inhibitor and method of use
DE69734149T2 (de) 1996-03-15 2006-07-06 Astrazeneca Ab Cinoline derivate und verwendung als heilmittel
EP0923376B1 (en) 1996-05-09 2004-11-03 Amrad Operations Pty.,Ltd. Use of steroids for treatment of asthma and airway diseases
JPH09316000A (ja) 1996-05-31 1997-12-09 Toagosei Co Ltd 血管新生抑制用ワクチン
US5958892A (en) 1996-07-30 1999-09-28 Board Of Regents, The University Of Texas System 2-methoxyestradiol-induced apoptosis in cancer cells
US5763432A (en) 1997-01-29 1998-06-09 Sri International Steriod inhibitors of estrone sulfatase and associated pharmaceutical compositions and methods of use
US6051726A (en) 1997-03-13 2000-04-18 Pharm-Eco Laboratories, Inc. Synthesis of 2-alkoxyestradiols
US6136992A (en) 1997-03-13 2000-10-24 The United States Of America As Represented By The Department Of Health And Human Services 2-alkoxy estradiols and derivatives thereof
CA2208916A1 (en) 1997-07-03 1999-01-03 Hyal Pharmaceutical Corporation Promotion of wound healing utilizing steroids having reduced deterioroussystemic side effects typical of glucocorticoids, mineralocorticoids andsex steroids
US6011023A (en) 1997-08-27 2000-01-04 Alcon Laboratories, Inc. Angiostatic steroids
US20020002294A1 (en) 1997-09-24 2002-01-03 D' Amato Robert J. Estrogenic compounds as antiangiogenic agents
EP1027045A4 (en) 1997-10-31 2004-12-08 Arch Dev Corp METHODS AND COMPILATIONS FOR REGULATING S-ALPHA REDUCTASE ACTIVITY
US6054446A (en) 1997-12-24 2000-04-25 Sri International Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use
US6046186A (en) * 1997-12-24 2000-04-04 Sri International Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use
JPH11209322A (ja) 1998-01-27 1999-08-03 Kao Corp イソバニリルアルコール誘導体
AU2994599A (en) 1998-03-06 1999-09-20 Imclone Systems Incorporated Active immunization against angiogenesis-associated antigens
KR20010043558A (ko) * 1998-05-13 2001-05-25 한센 핀 베네드, 안네 제헤르, 웨이콥 마리안느 감수분열 조절 화합물
US6413513B1 (en) 1998-05-22 2002-07-02 Entremed, Inc. Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
AU5144999A (en) 1998-08-07 2000-02-28 Endorecherche Inc. Inhibition of type 3 3alpha-hydroxysteroid dehydrogenase
CA2339835C (en) 1998-08-11 2008-12-16 Entremed, Inc. Use of estrogenic compounds as anti-fungal agents
AU5687199A (en) 1998-08-24 2000-03-14 Global Vascular Concepts, Inc. Use of anti-angiogenic agents for inhibiting vessel wall injury
US6284789B1 (en) 1998-09-04 2001-09-04 The Research Foundation Of State University Of New York Formation and composition of new optically active compounds
EP1126843A4 (en) 1998-10-29 2005-06-15 Bristol Myers Squibb Co AMINO-CELL DERIVATIVE COMPOUNDS INHIBITORS OF ENZYME IMPDH
US20060025393A1 (en) 1999-04-30 2006-02-02 Shutsung Liao Steroid derivatives
NZ515061A (en) 1999-04-30 2004-04-30 Sterix Ltd Use of a cyclic compound in cell cycling
GB9910934D0 (en) 1999-05-11 1999-07-14 Res Inst Medicine Chem Chemical compounds
US6730665B1 (en) 1999-05-12 2004-05-04 Mayo Foundation For Medical Education And Research Treatment of bone cancer
US7087592B1 (en) * 1999-08-23 2006-08-08 Entre Med, Inc. Compositions comprising purified 2-methoxyestradiol and methods of producing same
US6358940B1 (en) 1999-09-07 2002-03-19 Rutgers, The State University Modified 2-Alkoxyestradiol derivatives with prolonged pharmacological activity
AUPQ342599A0 (en) 1999-10-14 1999-11-04 University Of Melbourne, The Conjugates and uses thereof
US20020068724A1 (en) 2000-03-17 2002-06-06 Oncology Sciences Corporation Method and composition of novel compounds for the therapy and targeting of the primary modalities of cancer cell proliferation and homeostasis
US20030027803A1 (en) 2000-03-17 2003-02-06 Oncology Sciences Corporation Method and composition for inhibiting the incidence and proliferation of nervous system and brain cancer cells
US20020035098A1 (en) 2000-03-17 2002-03-21 Oncology Sciences Corporation Agents and methods for the prevention of initial onset and recurrence of existing cancers
US20040023863A1 (en) * 2000-04-06 2004-02-05 Franco Wayne P. Methods of use growth factors for treating heart disease
AU2001248849A1 (en) 2000-04-24 2001-11-07 Kyowa Hakko Kogyo Co. Ltd. Estra-1,3,5(10)-triene derivatives
CZ298835B6 (cs) 2000-05-11 2008-02-20 Research Institute For Medicine And Chemistry Inc. 2-substituované pregnatrienové a cholatrienové deriváty
AU2001279955A1 (en) * 2000-08-18 2002-03-04 Sterix Limited 2-substituted estradiol derivative for inhibiting superoxid dismutase
US20050192258A1 (en) 2000-08-18 2005-09-01 Agoston Gregory E. Antiangiogenic agents
US7135581B2 (en) 2000-08-18 2006-11-14 Entremed, Inc. Antiangiogenic agents
US6995278B2 (en) 2000-08-18 2006-02-07 Entre Med, Inc. Antiangiogenic agents
WO2002062347A1 (en) 2001-02-05 2002-08-15 Oncology Sciences Corporation Method and composition of novel compounds for the therapy and targeting of the primary modalities of cancer cell proliferation and homeostasis
US20040116397A1 (en) 2001-03-19 2004-06-17 Slaga Tom J Agents and methods for the prevention of initial onset of cancers, the treatment of cancers, and the recurrence of existing cancers
EP1260225A1 (en) 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
CA2447178C (en) 2001-05-18 2010-06-08 Christian Franz Holinka Pharmaceutical composition for use in hormone replacement therapy
WO2002100877A1 (en) 2001-06-11 2002-12-19 Southwest Foundation For Biomedical Research Novel 2-alkoxyestradiol analogs with antiproliferative and antimitotic activity
US6448419B1 (en) 2001-08-07 2002-09-10 Tetrionics, Inc. Synthesis of 2-hydroxyestradiol derivatives
JP2005501096A (ja) 2001-08-17 2005-01-13 ユニヴァーシティ オブ ピッツバーグ 肥満、代謝症候群、糖尿病、血管障害及び腎臓疾患を治療又は予防するエストラジオールメタボライトの投与
EP1446128B1 (en) 2001-11-15 2006-12-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
US20030175961A1 (en) * 2002-02-26 2003-09-18 Herron G. Scott Immortal micorvascular endothelial cells and uses thereof
US20040082558A1 (en) 2002-08-02 2004-04-29 Tofovic Stevan P. Administration of estradiol metabolites for inhibition of drug-induced nephrotoxicity
BRPI0407667A (pt) 2003-02-20 2006-03-01 Univ Pittsburgh metabólitos de estradiol para o tratamento de hipertensão pulmonar
US20050148565A1 (en) 2003-04-29 2005-07-07 Cooperwood John S. Use of aminoalkyloxy derivatives of 1,3,5(10)-Estratrien and -Estratetraene steroids in the treatment of breast cancer
US7687486B2 (en) 2003-04-29 2010-03-30 Florida Agricultural & Mechanical University Selective estrogen receptor modulators
EP1625143A4 (en) 2003-05-13 2009-09-30 Cryptopharma Pty Ltd ÖSTRATRIENDERIVATE
WO2005030120A2 (en) 2003-05-28 2005-04-07 Entremed, Inc. Antiangiogenic agents
US20070004689A1 (en) 2004-03-12 2007-01-04 Agoston Gregory E Antiangiogenic agents
EP1756139A4 (en) 2004-03-12 2009-07-29 Entremed Inc ANTI-ANGIOGENIC AGENTS
EP1819343A2 (en) 2004-11-29 2007-08-22 EntreMed, Inc. A method of administering anti-angiogenic agents and a method of treating disease using same

Similar Documents

Publication Publication Date Title
JP2006526025A5 (enExample)
JP2007529426A5 (enExample)
DE60118547T2 (de) Pharmazeutische zusammensetzung zur behandlung von kolorektalem krebs welche thalidomid und irinotecan enthält
CA2430669A1 (en) Synthesis of 3-amino-thalidomide and its enantiomers
DE602004004520T2 (de) Antineoplastische zusammensetzungen
CA2440037A1 (en) Benzimidazole derivatives for modulating the rage receptor
CN111801098A (zh) 使用阿匹莫德和谷氨酸能剂的组合疗法
JP2008521928A5 (enExample)
JP2020512337A5 (enExample)
JPWO1993013781A1 (ja) コレステロール低下剤
EP2089021B1 (en) Use of carboxyamidotriazole (cai) orotate in macular degeneration
AU764445B2 (en) Use of pyridazino(4,5-(b))indole-1-acetamide derivatives for preparing medicines for treating diseases related to the dysfunction of peripheral benzodiazepin receptors
JP2004529928A5 (enExample)
CA2373634A1 (en) Isophosphoramide mustard analogs and use thereof
JP5341521B2 (ja) タンパク質と結合パートナーとの相互作用を阻害するための化合物及び方法
JP2002514578A5 (enExample)
KR920016418A (ko) Nmda 길항제
CN118678958A (zh) 药物组合物及其用途
JP2019085404A (ja) 脳腫瘍の治療のための医薬
EP4157290A1 (en) Compositions, their uses in therapy and methods thereof
EP1107751B1 (de) Arzneimittel enthaltend platinkomplexverbindungen sowie deren verwendung
JPS58501375A (ja) 金属錯化合物及びこの化合物を含有する抗腫瘍形成剤
EP4009973B1 (en) Pharmaceutical compositions of (6as)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol
JP2015531355A (ja) 腫瘍治療のための薬剤組成物及びその適用
US12318368B2 (en) Physics-driven discovery of novel small therapeutic compounds for use as a BCL-2 inhibitor